BioSpace News Archive

Adaptive Biotechnologies Corporation announced a partnership with Epic to integrate the clonoSEQ® Assay into Epic’s comprehensive electronic medical record system.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced data demonstrating the potential of the Company’s novel platform to use various base editing strategies to successfully delete multiple cell surface targets from hematopoietic stem cells (HSCs), potentially enabling next-generation transplants for the treatment of acute myeloid leukemia (AML).

PDS Biotechnology Corporation today announced expanded interim data in the Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada).

Xtant Medical Holdings, Inc. today announced the closing of the second and final tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis.

TFF Pharmaceuticals, Inc. today shared further details on the poster presentations featuring the Company’s Thin Film Freezing Technology at the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting, which is being held in Boston from October 16-19, 2022.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be collaborating with NOCD, an organization that facilitates access to online therapy for people with obsessive-compulsive disorder (OCD) through its innovative telehealth platform.

Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced positive written feedback from the U.S. Food and Drug Administration (FDA) for its initial End-of-Phase 2 (EoP2) meeting request to discuss Chemistry, Manufacturing, and Controls (CMC) for its AQST-109 epinephrine sublingual film for the treatment of severe allergic reaction including anaphylaxis.

aTyr Pharma, Inc. today announced that it has entered into a research collaboration with Dualsystems Biotech AG, a company specializing in custom proteomics, aimed at accelerating drug discovery and generating new therapeutics based on aTyr’s extensive intellectual property.